DOCSLIB.ORG

HIV-1 Recombinant Poxvirus Vaccine Induces Cross-Protection Against HIV-2 Challenge in Rhesus Macaques

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIV-1 Recombinant Poxvirus Vaccine Induces Cross-Protection Against HIV-2 Challenge in Rhesus Macaques © 1995 Nature Publishing Group http://www.nature.com/naturemedicine .. .... ARTICLES HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques 1 2 ALASH'LE G. ABIMIKU , GENOVEFFA FRANCHINI', }AMES TARTAGLIA , KRISTINE ALDRICH', 1 3 4 MARIA MYAGKIKH , PHILLIP D. MARKHAM , PELE CHONG , MICHEL KLEIN\ 5 2 1 1 MARIE-PAULE KIENY , ENZO PAOLETTI , ROBERT C. GALL0 & MARJORIE ROBERT-GUROFF 'Laboratory of Tumor Cell Biology, Building 37, Room 6A09, 37 Convent Drive MSC 4255. National Cancer Institute, National Institutes ofHealth, Bethesda, Maryland 20892-4255, USA ' Virogenetics Corporation, 465 Jordan Road, Rensselaer Technology Park, Troy, New York 12180, USA 'Advanced BioScience Laboratories, Inc., 5510 Nicholson Lane, Kensington, Maryland 20895, USA ' Connaught Laboratories, 1755 Steeles Avenue West, Willowdale, Ontario, M2R 3T4, Canada 5Transgene, 11 rue de Molsheim, 67082 Strasbourg, France Correspondence should be addressed to M.R.G. Rhesus macaques were immunized with attenuated vaccinia or canarypox human Im­ munodeficiency virus type 1 (HIV-1) recombinants and boosted with HIV-1 protein sub­ units formulated In alum. Following challenge with HIV-2, •.....,, three out of eight immunized macaques resisted infection for six months and another exhibited signifi­ cantly delayed Infection, whereas all three naive controls became infected. Immuniza­ tions elicited both humoral and cellular immune responses; however, no clear correlates of protection were discerned. Although more extensive studies are now called for, this first demonstration of cross-protection between HIV-1 and -2 suggests that viral variabil­ ity may not be an Insurmountable problem In the design of a global AIDS vaccine. One of the main problems hindering HIV-1 vaccine develop­ function effectively as immunization vehicles... '0 (unpublished ment is the extensive variability of the virus. HIV-1 variants results). With respect to the use of these vectors in retrovirus not only are observed within and between infected individu­ vaccine development, an ALVAC recombinant expressing the als, but worldwide, eight distinct subtypes, A through H, have feline leukaemia virus (A subtype) Env and Gag proteins was been described'. A ninth grouping, subtype 0, is composed of shown to afford protection in cats against the development of even more highly divergent members. As a result of this het­ persistent viraemia when challenged with virus simultane­ 11 erogeneity, design of an effective vaccine for even a geograph­ ously given in the mouth and sprayed on the nose • More­ ically restricted area is a daunting task. The problem is over, protocols consisting of an ALVAC-HIV-1MN gp160 compounded on a global scale, where tailoring of vaccines to recombinant followed by boosting with native envelope pro­ specific populations is a current strategy. tein (gp120) demonstrated the ability of the ALVAC-HIV-1 re­ Although HIV-2 is clearly related to HIV-1 structurally and combinant to prime HIV-1 specific humoral and cellular functionally, it nevertheless constitutes a different viral type. immune responses in Phase I human trials, even in individu­ The viruses exhibit limited homology, with only 40 to 60% als previously exposed to vaccinia 0.-L. Excler, oral presenta­ similarity in the amino acid sequences of the structural gene tion, Septieme colloque des "Cent Gardes", 1992). 2 products • Although less pathogenic and infectious than HIV- Lack of an affordable, readily available, and proven animal 1, HIV -2 also causes AIDS, albeit with a slower disease model for HIV-1 has greatly hindered vaccine research. The courseJ-'. HIV-2 is endemic in West Africa, and has become a chimpanzee is inappropriate on the first two counts, and the 12 growing public health problem. Therefore, our AIDS vaccine pig-tailed macaque (Macaca nemestrina) model , although studies have addressed not only HIV-1 but also HIV-2, in part promising, has yet to be proven reliable. For these reasons we as a model for HIV-1, but also as a legitimate candidate itself have chosen to use the rhesus macaque (M. mulatta) system. for vaccine development. This species has been shown to be susceptible to infection not Our investigations have focussed on attenuated poxvirus only by several simian immunodeficiency virus (SIV) strains recombinants as vaccine vehicles. NYV AC, derived from the but also by HIV-2 (ref. 13-16), thus allowing not only assess­ Copenhagen vaccinia virus vaccine strain, was attenuated by ment of HIV-2 vaccine efficacy, but also evaluation of HIV-1 the precise deletion of 18 open reading frames implicated in vaccine immunogenicity followed by heterologous cross-chal­ poxvirus virulence•·•. The naturally attenuated ALVAC is a ca­ lenge experiments. nary poxvirus vector system that is unable to productively In separate studies a lasting protection against HIV -2 infec­ replicate in non-avian species•·•. Despite their highly attenu­ tion of rhesus macaques (G. Franchini et al., manuscript sub­ ated phenotype, NYV AC and AL VAC have been shown to mitted) and human T-cellleukaemia/lymphoma virus type I NATIJRE MEDICINE, VOLUME I, NUMBER 4 APRIL 1995 321 © 1995 Nature Publishing Group http://www.nature.com/naturemedicine • ········ ARTICLES .... ...... ..... Weeks Post Inoculation D II il il il i I I I I I , I I I I I 10 20 30 40 50 60 70 80 90 100 110 120 130 20 ~ Rhesus 214L (NYVACgp160 + octamerlcV3) & '& ;!!. (") Q)N 1.5 t 15 <g2: ,...,~~ ~.p_ 1.0 10 -'< w.,o-'o~ 0 ~ · .o~ ~ <(- 0.5 - t 5 :> . I ~ (3300) 2000 <..:><0 w~ 1500 OJO ~~ -s· "'m """'"' 40 1000 8l ~ c · ~ i= 2: =~ = >-J: ::i- ~g<i 20 500 ~§1 Q) ·..: ~ zc:> t <~ & Rhesus 218L (NYVACgp120 + octamerlcV3) 20 ~ ;!!. Q)N 1.5 c. 15 cnO ~g~ =-~ ~.e~- 1.0 IT~ uJgo ~(f) .o~ <t- 0.5 t 5 2: i J: (3000) ~~ 1ooo . i 2000 C>j!! <)' 100 10 1500 · ~F2: = >-J: ~g <:i 40 1000 20 ~'§;: 500 <( ~ t - Recombinant Vector c::::> Octameric V3 ~Challenge : HIV-2 ssL6669 Fig. 1 Immune responses in rhesus macaques inoculated with NYVAC-HIV-1,,, gp160 or gp120, and boosted with octameric V3 peptide. Macaque 214L (top two panels) was immunized (closed arrows) with the NYVAC-HIV-1 "" gp160 recombinant, vP911, and macaque 218L (lower two panels) with the NYVAC-HIV-1 "" gp120 recombinant vP921. Both macaques were boosted (open arrows) with a mixed octameric V3 loop peptide preparation . The final boost with NYVAC recombinants consisted of 108 pfu for macaque 214L and 1 o• pfu for macaque 218L. cell-mediated immune responses marked with an asterisk (•) were obtained with HIV-2 antigens and targets. The time of challenge , with HIV-2 58 6669 is indicated by the large hatched arrow. (HTLV-1) infection of rabbits" has been demonstrated follow­ combinants and proteins for vaccinating rhesus macaques ing immunization with HIV-2 or HTLV-1 recombinant vaccine against HIV-2 (G. Franchini et al., manuscript submitted). At candidates constructed in either NYV AC or ALVAC vectors. To the conclusion of the immunogenicity studies, we evaluated pursue these promising vectors as HIV-1 candidate vaccines, the protection afforded by the immunization regimens against we first evaluated the immunogenicity of a number of NYV AC a heterologous cross challenge with HIV-2. and ALVAC recombinants carrying HIV-1 genes (gag, pol, env) As expected our results showed that the NYV AC and AL VAC followed by various viral proteins or peptides presented with recombinants primed both humoral and cellular immune re­ adjuvants in eight rhesus macaques. Our objectives were (1) to sponses to HIV-1. But remarkably, following live virus chal­ compare the priming ability of recombinants expressing both lenge SO% of the immunized animals resisted infection by HIV-1 Env proteins (gp120, gp41) versus simply the gpl20 HIV -2, while all three naive controls became infected. This moiety alone; (2) to evaluate recombinants carrying the full finding, although preliminary, suggests that viral variability complement of HIV-1 genes for viral structural proteins gag, may not necessarily preclude effective AIDS vaccine develop­ pol, and env, as well as those carrying just the env gene; (3) to ment. It should encourage further investigation of cross-pro­ compare directly NYVAC- and ALVAC-HIV-1 recombinants in tection in other heterologous systems as well as stimulate similar prime/ boost protocols; and (4) to compare these re­ research on immunologically conserved epitopes and poten­ sults with those obtained using NYV AC- and ALVAC-HIV-2 re- tially novel protective mechanisms. 322 NATURE MEDICINE, VOLUME 1, NUMBER 4 APRIL 1995 © 1995 Nature Publishing Group http://www.nature.com/naturemedicine • ··············ARTICLES Results tion (Fig. 2), two subunit booster inoculations were necessary lmmunogenicity of HIV-1 recombinants and boosts to elicit neutralizing antibody activity and also led to more Eight rhesus macaques were inoculated with NYV AC- or regularly detectable Env-specific T-cell proliferative responses ALVAC-HIV-1 recombinants and subsequently boosted with and cytolytic activities. Additional booster inoculations, ei­ peptides or HIV-1 proteins formulated in alum or with addi­ ther with subunit preparations or recombinants, had little ef­ tional ALVAC/NYVAC-HIV-1 recombinants (see Methods). fect on subsequent immune responses. Animals boosted with Macaques were bled at intervals and sera were assayed for anti­ native gp120 (Fig. 2) developed higher neutralizing antibody bodies to the entire HIV-1 envelope protein and the V3loop, a titres compared to those boosted with the octameric V3 pep­ 21 principal neutralizing determinant of the virus'.._ , and for tide (Fig. 1), although the latter macaques exhibited higher neutralizing antibodies. Peripheral blood mononuclear cells V3 loop binding titres, suggesting that native gp120 elicited (PBMC) were monitored for HIV-1-specific lymphocyte prolif­ neutralizing antibodies to epitopes in addition to the V3 loop. erative responses as well as cytolytic activities. The HIV-spe­ This is further indicated by the independent fluctuation of cific immune responses observed are in Figs 1-4.
Load more

Recommended publications
  • Evaluation of T-Cell and B-Cell Epitopes and Design of Multivalent Vaccines Against Htlv-1 Diseases
    EVALUATION OF T-CELL AND B-CELL EPITOPES AND DESIGN OF MULTIVALENT VACCINES AGAINST HTLV-1 DISEASES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Roshni Sundaram, M.S. * * * * * The Ohio State University 2003 Dissertation Committee: Approved by Professor Pravin T.P. Kaumaya, Adviser Professor Christopher M. Walker Adviser Professor Neil R. Baker Department of Microbiology Professor Marshall V. Williams ABSTRACT Human T-cell lymphotropic virus type I (HTLV-1) is a C type retrovirus that is the causative agent of an aggressive T-cell malignancy, adult T-cell leukemia/lymphoma (ATLL). The virus is also implicated in a number of inflammatory disorders, the most prominent among them being HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP). HTLV-1, like many viruses that cause chronic infection, has adapted to persist in the face of an active immune response in infected individuals. The viral transactivator Tax is the primary target of the cellular immune response and humoral responses are mainly directed against the envelope protein. Vaccination against HTLV-1 is a feasible option as there is very little genetic and antigenic variability. Vaccination regimes against chronic viruses must be aimed at augmenting the immune response to a level that is sufficient to clear the virus. This requires that the vaccine delivers a potent stimulus to the immune system that closely resembles natural infection to activate both the humoral arm and the cellular arm. It is also clear that multicomponent vaccines may be more beneficial in terms of increasing the breadth of the immune response as well as being applicable in an outbred population.
    [Show full text]
  • Evolution of the PRD1-Adenovirus Lineage: a Viral Tree of Life Incongruent with the Cellular 3 Universal Tree of Life 4 5 Authors 6 Anthony C
    bioRxiv preprint doi: https://doi.org/10.1101/741942; this version posted August 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title 2 Evolution of the PRD1-adenovirus lineage: a viral tree of life incongruent with the cellular 3 universal tree of life 4 5 Authors 6 Anthony C. Woo1,2*, Morgan Gaia1,2, Julien Guglielmini3, Violette Da Cunha1,2 and Patrick 7 Forterre1,2* 8 9 Affiliations 1 10 Unité de Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Department of 11 Microbiology, Institut Pasteur, 25-28 Rue du Docteur Roux, 75015 Paris, France. 2 12 Department of Microbiology, CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, 13 Institute for Integrative Biology of the Cell (I2BC), Bâtiment 21, Avenue de la Terrasse, 14 91190 Gif-sur-Yvette cedex, France. 3 15 HUB Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Institut Pasteur, 25-28 16 Rue du Docteur Roux, 75015 Paris, France 17 *corresponding authors: 18 Anthony Woo: [email protected] 19 Patrick Forterre: [email protected] 20 21 Abstract 22 Double-stranded DNA viruses of the PRD1-adenovirus lineage are characterized by 23 homologous major capsid proteins containing one or two β-barrel domains known as the jelly 24 roll folds. Most of them also share homologous packaging ATPases of the FtsK/HerA 25 superfamily P-loop ATPases. Remarkably, members of this lineage infect hosts from the three 26 domains of life, suggesting that viruses from this lineage could be very ancient and share a 27 common ancestor.
    [Show full text]
  • Herpes Simplex Virus Type 1 Oril Is Not Required for Virus Infection In
    JOURNAL OF VIROLOGY, Nov. 1987, p. 3528-3535 Vol. 61, No. 11 0022-538X/87/113528-08$02.00/0 Copyright C 1987, American Society for Microbiology Herpes Simplex Virus Type 1 oriL Is Not Required for Virus Replication or for the Establishment and Reactivation of Latent Infection in Mice MARYELLEN POLVINO-BODNAR, PAULO K. ORBERG, AND PRISCILLA A. SCHAFFER* Laboratory of Tumor Virus Genetics, Dana-Farber Cancer Institute, and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115 Received 11 May 1987/Accepted 31 July 1987 During the course of experiments designed to isolate deletion mutants of herpes simplex virus type 1 in the gene encoding the major DNA-binding protein, ICP8, a mutant, d61, that grew efficiently in ICP8-expressing Vero cells but not in normal Vero cells was isolated (P. K. Orberg and P. A. Schaffer, J. Virol. 61:1136-1146, 1987). d61 was derived by cotransfection of ICP8-expressing Vero cells with infectious wild-type viral DNA and a plasmid, pDX, that contains an engineered 780-base-pair (bp) deletion in the ICP8 gene, as well as a spontaneous -55-bp deletion in OriL. Gel electrophoresis and Southern blot analysis indicated that d61 DNA carried both deletions present in pDX. The ability of d61 to replicate despite the deletion in OriL suggested that a functional OriL is not essential for virus replication in vitro. Because d61 harbored two mutations, a second mutant, ts+7, with a deletion in oriL-associated sequences and an intact ICP8 gene was constructed. Both d61 and ts+7 replicated efficiently in their respective permissive host cells, although their yields were slightly lower than those of control viruses with intact oriL sequences.
    [Show full text]
  • Topological Analysis of the Gp41 MPER on Lipid Bilayers Relevant to the Metastable HIV-1 Envelope Prefusion State
    Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state Yi Wanga,b, Pavanjeet Kaurc,d, Zhen-Yu J. Sune,1, Mostafa A. Elbahnasawya,b,2, Zahra Hayatic,d, Zhi-Song Qiaoa,b,3, Nhat N. Buic, Camila Chilea,b,4, Mahmoud L. Nasre,5, Gerhard Wagnere, Jia-Huai Wanga,f, Likai Songc, Ellis L. Reinherza,b,6, and Mikyung Kima,g,6 aLaboratory of Immunobiology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; bDepartment of Medicine, Harvard Medical School, Boston, MA 02115; cNational High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 32306; dDepartment of Physics, Florida State University, Tallahassee, FL 32306; eDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; fDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; and gDepartment of Dermatology, Harvard Medical School, Boston, MA 02215 Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 23, 2019 (received for review July 18, 2019) The membrane proximal external region (MPER) of HIV-1 envelope immunologically vulnerable epitopes targeted by several of the most glycoprotein (gp) 41 is an attractive vaccine target for elicitation of broadly neutralizing antibodies (bNAbs) developed during the broadly neutralizing antibodies (bNAbs) by vaccination. However, course of natural HIV-1 infection (10–13). Insertion, deletion, current details regarding the quaternary structural organization of and mutations of residues in the MPER defined the functional the MPER within the native prefusion trimer [(gp120/41)3] are elu- importance of the MPER in Env incorporation, viral fusion, and sive and even contradictory, hindering rational MPER immunogen infectivity (14–16).
    [Show full text]
  • A Brief Speculative History of Avipoxvirus in New Zealand
    A brief, speculative history of avipoxvirus in New Zealand Brett Gartrell, Laryssa Howe, Maurice Alley, Hye-Jeong Ha Intro to avipoxvirus (APV) • Global distribution • Reports in >280 bird species, 70 families, 20 orders globally • Economic losses in domestic poultry • Biodiversity losses in island ecosystems (Hawaii, Galapagos, Canary Islands) in conjunction with avian malaria (vaccinia virus, copyright E. Niles). APV infection characteristics • Excellent environmental stability • Need a break in the epithelium for infection to establish • Insect and mechanical vectors are main route of infection • Host specificity varies between strains APV molecular characteristics • Fowlpox virus is the type species of the Avipoxvirus genus • complete genomic sequences of Fowlpox virus and Canarypox virus • The two genomes are highly diverged, sharing only ca. 70% sequence identity • The 365-kbp genome of Canarypox virus is larger than that of Fowlpox virus (288 kbp) and shows significant differences in gene content APV phylogeny • Initially assigned strain/species status on host affected but confused by multi-host pathogenic strains • DNA sequences of the 4b core protein coding genomic region currently used. • Wide variation in genome has limited other pan-genus PCR primers • the vast majority of avian poxvirus isolates clustered into three major clades, represented by the Fowlpox virus (clade A), the Canarypox virus (clade B), and the Psittacinepox virus (clade C) APV phylogeny from NZ birds (HJ Ha PhD) Silvereye © P Sorrell Ha, H.J., Howe, L., Alley, M., Gartrell, B. 2011. The phylogenetic analysis of avipoxvirus in New Zealand. Veterinary Microbiology 150: 80–87 APV distribution in NZ Ha, H.J., Howe, L., Alley, M., Gartrell, B.
    [Show full text]
  • Viroporins: Structures and Functions Beyond Cell Membrane Permeabilization
    Editorial Viroporins: Structures and Functions beyond Cell Membrane Permeabilization José Luis Nieva 1,* and Luis Carrasco 2,* Received: 17 September 2015 ; Accepted: 21 September 2015 ; Published: 29 September 2015 Academic Editor: Eric O. Freed 1 Biophysics Unit (CSIC, UPV/EHU) and Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080 Bilbao, Spain 2 Centro de Biología Molecular Severo Ochoa (CSIC, UAM), c/Nicolás Cabrera, 1, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain * Correspondence: [email protected] (J.L.N.); [email protected] (L.C.); Tel.: +34-94-601-3353 (J.L.N.); +34-91-497-8450 (L.C.) Viroporins represent an interesting group of viral proteins that exhibit two sets of functions. First, they participate in several viral processes that are necessary for efficient production of virus progeny. Besides, viroporins interfere with a number of cellular functions, thus contributing to viral cytopathogenicity. Twenty years have elapsed from the first review on viroporins [1]; since then several reviews have covered the advances on viroporin structure and functioning [2–8]. This Special Issue updates and revises new emerging roles of viroporins, highlighting their potential use as antiviral targets and in vaccine development. Viroporin structure. Viroporins are usually short proteins with at least one hydrophobic amphipathic helix. Homo-oligomerization is achieved by helix–helix interactions in membranes rendering higher order structures, forming aqueous pores. Progress in viroporin structures during the last 2–3 years has in some instances provided a detailed knowledge of their functional architecture, including the fine definition of binding sites for effective inhibitors.
    [Show full text]
  • How Influenza Virus Uses Host Cell Pathways During Uncoating
    cells Review How Influenza Virus Uses Host Cell Pathways during Uncoating Etori Aguiar Moreira 1 , Yohei Yamauchi 2 and Patrick Matthias 1,3,* 1 Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland; [email protected] 2 Faculty of Life Sciences, School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK; [email protected] 3 Faculty of Sciences, University of Basel, 4031 Basel, Switzerland * Correspondence: [email protected] Abstract: Influenza is a zoonotic respiratory disease of major public health interest due to its pan- demic potential, and a threat to animals and the human population. The influenza A virus genome consists of eight single-stranded RNA segments sequestered within a protein capsid and a lipid bilayer envelope. During host cell entry, cellular cues contribute to viral conformational changes that promote critical events such as fusion with late endosomes, capsid uncoating and viral genome release into the cytosol. In this focused review, we concisely describe the virus infection cycle and highlight the recent findings of host cell pathways and cytosolic proteins that assist influenza uncoating during host cell entry. Keywords: influenza; capsid uncoating; HDAC6; ubiquitin; EPS8; TNPO1; pandemic; M1; virus– host interaction Citation: Moreira, E.A.; Yamauchi, Y.; Matthias, P. How Influenza Virus Uses Host Cell Pathways during 1. Introduction Uncoating. Cells 2021, 10, 1722. Viruses are microscopic parasites that, unable to self-replicate, subvert a host cell https://doi.org/10.3390/ for their replication and propagation. Despite their apparent simplicity, they can cause cells10071722 severe diseases and even pose pandemic threats [1–3].
    [Show full text]
  • Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Yellow-Eyed Penguin (Megadyptes Antipodes)
    viruses Article Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Yellow-Eyed Penguin (Megadyptes antipodes) Subir Sarker 1,* , Ajani Athukorala 1, Timothy R. Bowden 2,† and David B. Boyle 2 1 Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, VIC 3086, Australia; [email protected] 2 CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, VIC 3220, Australia; [email protected] (T.R.B.); [email protected] (D.B.B.) * Correspondence: [email protected]; Tel.: +61-3-9479-2317; Fax: +61-3-9479-1222 † Present address: CSIRO Australian Animal Health Laboratory, Australian Centre for Disease Preparedness, Geelong, VIC 3220, Australia. Abstract: Emerging viral diseases have become a significant concern due to their potential con- sequences for animal and environmental health. Over the past few decades, it has become clear that viruses emerging in wildlife may pose a major threat to vulnerable or endangered species. Diphtheritic stomatitis, likely to be caused by an avipoxvirus, has been recognised as a signifi- cant cause of mortality for the endangered yellow-eyed penguin (Megadyptes antipodes) in New Zealand. However, the avipoxvirus that infects yellow-eyed penguins has remained uncharacterised. Here, we report the complete genome of a novel avipoxvirus, penguinpox virus 2 (PEPV2), which was derived from a virus isolate obtained from a skin lesion of a yellow-eyed penguin. The PEPV2 genome is 349.8 kbp in length and contains 327 predicted genes; five of these genes were found to be unique, while a further two genes were absent compared to shearwaterpox virus 2 (SWPV2).
    [Show full text]
  • Assembly Lecture 11 Biology W3310/4310 Virology Spring 2014
    Assembly Lecture 11 Biology W3310/4310 Virology Spring 2014 “Anatomy is des.ny.” --SIGMUND FREUD All virions complete a common set of assembly reac3ons * common to all viruses common to many viruses ©Principles of Virology, ASM Press The structure of a virus parcle determines how it is formed ©Principles of Virology, ASM Press Assembly is dependent on host cell machinery • Cellular chaperones • Transport systems • Secretory pathway • Nuclear import and export machinery Concentrang components for assembly: Nothing happens fast in dilute solu1ons • Viral components oSen visible by light microscopy (‘factories’ or ‘inclusions’) • Concentrate proteins on internal membranes (poliovirus) • Negri bodies (rabies virus) Viral proteins have ‘addresses’ built into their structure • Membrane targeYng: Signal sequences, fa\y acid modificaons • Membrane retenYon signals • Nuclear localizaYon sequences (NLS) • Nuclear export signals 414 Localiza3on of viral proteins to the nucleus CHAPTER 12 Golgi apparatus Ribosome Rough endoplasmic reticulum Plasma membrane Py(VP1) + VP2/3 Ad hexon + 5 100 kDa Nuclear envelope: Outer nuclear membrane Inner nuclear membrane Nucleus Nuclear pore complex Mitochondrion Cytoskeleton: Influenza virus NP Intermediate filament Microtubule Actin filament bundle Extracellular matrix ©Principles of Virology, ASM Press Figure 12.1 Localization of viral proteins to the nucleus. The nucleus and major membrane-bound compartments of the cytoplasm, as well as components of the cytoskeleton, are illustrated schematically and not to scale. Viral proteins destined for the nucleus are synthesized by cytoplasmic polyribosomes, as illustrated for the infl uenza virus NP protein. They engage with the cytoplasmic face of the nuclear pore complex and are translocated into the nucleus by the protein import machinery of the host cell.
    [Show full text]
  • Ube1a Suppresses Herpes Simplex Virus-1 Replication
    viruses Article UBE1a Suppresses Herpes Simplex Virus-1 Replication Marina Ikeda 1 , Akihiro Ito 2, Yuichi Sekine 1 and Masahiro Fujimuro 1,* 1 Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan; [email protected] (M.I.); [email protected] (Y.S.) 2 Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-75-595-4717 Academic Editors: Magdalena Weidner-Glunde and Andrea Lipi´nska Received: 7 November 2020; Accepted: 1 December 2020; Published: 4 December 2020 Abstract: Herpes simplex virus-1 (HSV-1) is the causative agent of cold sores, keratitis, meningitis, and encephalitis. HSV-1-encoded ICP5, the major capsid protein, is essential for capsid assembly during viral replication. Ubiquitination is a post-translational modification that plays a critical role in the regulation of cellular events such as proteasomal degradation, protein trafficking, and the antiviral response and viral events such as the establishment of infection and viral replication. Ub-activating enzyme (E1, also named UBE1) is involved in the first step in the ubiquitination. However, it is still unknown whether UBE1 contributes to viral infection or the cellular antiviral response. Here, we found that UBE1a suppressed HSV-1 replication and contributed to the antiviral response. The UBE1a inhibitor PYR-41 increased HSV-1 production. Immunofluorescence analysis revealed that UBE1a highly expressing cells presented low ICP5 expression, and vice versa. UBE1a inhibition by PYR-41 and shRNA increased ICP5 expression in HSV-1-infected cells.
    [Show full text]
  • Safety of Intravenous Administration of a Canarypox Virus Encoding The
    Cancer Gene Therapy (2003) 10, 509–517 r 2003 Nature Publishing Group All rights reserved 0929-1903/03 $25.00 www.nature.com/cgt Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients Anand G Menon,1 Peter JK Kuppen,1 Sjoerd H van der Burg,2 Rienk Offringa,2 Marie Claude Bonnet,5 Bert IJ Harinck,1 Rob AEM Tollenaar,1 Anke Redeker,2 Hein Putter,4 Philippe Moingeon,5 Hans Morreau,3 Cornelis JM Melief,2 and Cornelis JH van de Velde1 1Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, The Netherlands; 3Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands; and 5Aventis Pasteur, Lyon, France. Overexpression of p53 occurs in more than 50% of colorectal cancers. Therefore, p53 represents an attractive target antigen for immunotherapy. We assessed the safety of a canarypox virus encoding the human wild-type p53 gene given intravenously to end- stage colorectal cancer patients in a three-step dose escalation study aimed at inducing p53 immune responses. Patients with metastatic disease of p53-overexpressing colorectal cancers were vaccinated three times at 3-week intervals, each time with 106.5 7.0 7.5 CCID50 (CCID50 ¼ cell culture infectious dose 50%; group 1, n ¼ 5), 10 CCID50 (group 2, n ¼ 5) or 10 CCID50 (group 3, n ¼ 6). Vital signs and the occurrence of adverse events were monitored and blood was analyzed for biochemical and hematological parameters as well as signs of auto-immune safety.
    [Show full text]
  • Avian Pox in Shearwaters on Lord Howe Island
    Association of Avian Veterinarians Australasian Committee Ltd. Annual Conference Proceedings Auckland New Zealand 2017. 25: 63-68. Avian Pox in Shearwaters on Lord Howe Island Subir Sarker1, Shubhagata Das2, Jennifer L. Lavers3, Ian Hutton4, Karla Helbig1, Chris Upton5, Jacob Imbery5, and Shane R. Raidal2 1. Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, VIC, 3086 2. School of Animal and Veterinary Sciences, Charles Sturt University, NSW 2678 3. Institute for Marine and Antarctic Studies, University of Tasmania, TAS 7004 4. Lord Howe Island Museum, Lord Howe Island, NSW 2898 5. Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada. Abstract fungal infections are common and contribute to mortality (van Riper and Forrester, 2007). Until recently six avipox- Avipoxvirus infections occur in a wide range of bird spe- virus genomes were published; a pathogenic American cies worldwide. In Australia pox is common in the Aus- strain of Fowlpox virus (Afonso et al., 2000), an attenuat- tralian magpie (Cracticus tibicen), Currawongs (Strepera ed European strain of Fowlpox virus (Laidlaw and Skinner spp.) and Silvereyes (Zosterops lateralis) but very little , 2004), a virulent Canarypox virus (Tulman et al., 2004), a is known about the evolution of this family of viruses pathogenic South African strain of Pigeonpox virus, a Pen- or the disease ecology of avian poxviruses in seabirds. guinpox virus (Offerman et al., 2014) and a pathogenic Pox lesions have been seen in colonies of Shy Albatross Hungarian strain of Turkeypox virus (Banyai et al., 2015). (Thalassarche cauta) in Bass Strait but the epidemiology of pox in pelagic birds is not very well elucidated.
    [Show full text]